Plasma renin activity (PRA) and aldosterone secretion rate (ASR) were measured in 22 patients in balance on a 100 mEq sodium diet during the malignant phase of hypertension and at intervals during long-term follow-up on pharmacological therapy. Three patients had normal PRA and ASR during malignant hypertension. Eighty-six per cent of patients had an increased ASR, but only in 36% was PRA concomitantly increased during malignant hypertension (one patient developed elevated PRA in the postmalignant period). PRA fell to normal in 87% of patients after antihypertensive therapy. ASR fell to normal on drug therapy in six patients, and in all of these there was a period during the postmalignant phase in which ASR was increased while PRA was normal or suppressed. In addition to this group with reversible hyperaldosteronism, all but two of the remaining patients with elevated ASR had periods during which ASR was increased at the same time that PRA was normal or suppressed. These data raise the possibility that either a nonrenin aldosterone-stimulating hormone is secreted in malignant hypertension or that excessive stimulation of the adrenal by angiotensin can lead to persistent hyperfunction of aldosterone-secreting cells with a quantitatively deranged feedback control. One patient had an aldosterone-secreting adenoma and had manifestations of the hyperaldosteronism antedating the development of malignant hypertension.
• The central feature of malignant hypertension is a progressive arteriolopathy, manifested clinically by changes in the optic fundus, kidney, brain, and other organs. The arteriolopathy is thought to result from severely elevated arterial pressure, and healing of the vascular lesions follows sustained blood presFrom the Departments of Medicine, Pharmacology, and Surgery, Veterans Administration Hospital and Vanderbilt University School of Medicine, Nashville, Tennessee.
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sure reduction, both in the rabbit 1 and in man. 2 The present study was designed to examine the hypothesis that the renin hypersecretion in malignant hypertension 3 -8 results from renal arteriolopathy rather than causes it. Pharmacological therapy was used as a way of removing the proposed initiating factor, the high arterial pressure, in an attempt to determine the degree and frequency with which this intervention would restore renin hypersecretion to normal. Scattered reports have suggested that renin 7 and aldosterone 8 -9 overproduction may be reversed with therapy, but Brown has argued that this merely reflects changes in sodium balance. 7 This investigation prospectively evaluated the effects of therapy on renin hypersecretion and aldosterone secre-
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tion concomitantly in patients with malignant hypertension, employing conditions that eliminated changing sodium balance as a variable. Aldosterone-producing adenomas have been thought not to cause malignant hypertension. 10 '
n Kaplan, however, has clearly documented one case of this association. 12 The present series adds still further evidence that aldosterone-secreting rumors can lead to malignant hypertension.
Except for aldosterone-producing adenomas it has been widely assumed that the elevated aldosterone secretion found in malignant hypertension is secondary to renin hypersecretion 8 ' 13 and that aldosterone secretion would vary as a function of renin. It was therefore surprising to find a period of dissociation between renin and aldosterone during the recovery phase of malignant hypertension, in which aldosterone secretion remains elevated after renin has fallen to or below normal levels.
Methods
Twenty-two patients with malignant hypertension were studied. All had severe hypertension with a diastolic blood pressure of at least 120 mm Hg, and papilledema was present on admission. In order to assure a prognosis sufficiently good for long-term follow-up, no patient was included whose serum urea nitrogen exceeded 70 mg% once initial control of the blood pressure was obtained. The investigations were conducted in the Vanderbilt University Hospital and its Clinical Research Center.
The patient group included 13 men and 9 women, ranging in age from 25 to 56 years. After admission to the hospital, the patient's blood pressure was brought under control by pharmacological means, including the use of methyldopa, guanethidine, hydralazine, pentolinium, and diuretics; occasionally, in severe cases salt restriction was employed initially. Whenever possible, a blood sample for assay of plasma renin activity was drawn immediately on admission before therapy was begun. Once the clinical condition was stable, patients were evaluated for the presence of a surgically correctible cause of hypertension, with studies including rapid-sequence intravenous pyelography, renal arteriography, and measurement of urinary 17-hydroxycorticosteroid 14 and total urinary catecholamine 15 excretion. If no evidence of renal artery stenosis, pheochromocytoma, or cortisol overproduction was found, the patient was begun on this study, Supplement II to Chcuhutm Ruench, Volt. XXVIII and XXIX, which includes most of the patients meeting the above criteria seen at this hospital center between mid-1965 and 1969.
As soon as possible after admission, patients were placed on a dietary intake calculated to contain 100 mEq per day of sodium, and diuretics were discontinued. Adequate potassium supplementation was given to raise the serum potassium above 3.5 rnEq/L, but supplemental potassium was not administered on the days when aldosterone secretion was measured. Blood pressure was maintained within an acceptable range by the use of methyldopa and/or guanethidine; one patient (C.P.) received adjunctive hydralazine during three of his eight study periods. Blood pressure measurements were made four times daily after ten minutes in the supine position and after two minutes standing. The excretion of urinary sodium and potassium was measured daily by flame photometry.
Plasma renin activity (PRA) and aldosterone secretion rate (ASR) were determined when the patient was in balance on a 100 mEq per day sodium intake during the initial and all follow-up studies. In addition, selected studies were carried out with patients in balance on diets calculated to contain 10 mEq/day sodium.
Blood samples for assay of PRA were obtained after the patient had been supine for eight hours, then again after three hours of ambulatory activity. PRA was measured by the method of Boucher et al., 18 and results are expressed as nanograms of angiotensin, generated during a three-hour incubation, per 100 ml of plasma. Determinations of supine and ambulatory PRA usually were made twice during each study period, and the average value is presented in the tables and figures.
Values for PRA in normal subjects as determined in this laboratory are presented in Table 1 . For statistical analysis each PRA determination was considered as an independent value, and results within individuals were not grouped. Mean values for each category were obtained; normal limits (to include 95% of the population) were calculated, assuming a log normal distribution of renin values because of the skewed nature of the results. 17 The ASR was measured at least once during each study period with an isotope-dilution technique. 18 Collection periods were extended to 48 or 72 hours in patients with impaired renal function. Results are expressed as micrograms of aldosterone secreted per 24 hours. In this laboratory the upper limit of normal for ASR on a 100 mEq sodium diet is 160 fig/24 hr.
After the initial period of study, patients were kept in the hospital for about three weeks. After discharge they were followed as outpatients at *Ten subjects were studied on a 100-mEq and 11 subjects on a 10-mEq sodium diet. CL confidence limits; n = number of separate samples drawn for analysis.
appropriate intervals by one of the authors with blood pressure control maintained by a combination of thiazide diuretics, methyldopa, guanethidine, bethanidine, hydralazine, and dietary sodium restriction. Subsequently, patients were readmitted at varying intervals for follow-up evaluation of ASR and PRA according to the above protocol.
In a small number of patients, further studies were performed to exclude the likelihood of aldosterone-producing adenoma, including determination of the response of renin to sodium restriction 11 and evaluation of the effect on the ASR of dexamethasone 19 and desoxycorticosterone acetate. 20 For these studies a control determination of the ASR was followed by the *PRA = plasma renin activity (ng/100 ml/3 hr). fASR = aldosterone secretion rate (/ig/24 hr). {Within a few hours of admission to the hospital and before drug therapy. 
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oral administration of dexamethasone, 2.0 mg/ day in four divided doses, with the ASR repeated after two days of drug. Several days later, desoxycorticosterone acetate was given parenterally, 20 mg/day in two divided doses; after three days of medication, the ASR was again determined.
Results
PLASMA RENIN ACTIVITY AND ALDOSTERONE SECRETION RATE DURING THE INITIAL ADMISSION WITH MALIGNANT HYPERTENSION
PRA and ASR were measured during 23 studies conducted during the initial admission for the malignant phase of hypertension in 22 patients (Table 2 ). Patient J.W. was studied twice; after his first admission with malignant hypertension, he was lost to follow-up and returned two years later with a second episode of malignant hypertension.
Three patients with clear evidence of malignant hypertension had normal PRA and normal ASR initially (Tables 2 and 4 ), indicating that derangements in this hormonal system are not requisite for malignant hypertension. ASR was elevated in 19 of the 22 patients (86%) during the initial admission and when in balance on a 100 mEq sodium diet. Those patients with elevated aldosterone secretion had values ranging from 225 to 773 /u.g/24 hr (upper limit of normal for these balance conditions is 160 /u-g/24 hr). In contrast, only eight patients (36%) had elevated PRA under the same conditions (group II, Table 2 ). In the remaining patients with high ASR, PRA was either normal or low ( only eight patients before therapy was begun and sodium balance achieved. The time between admission to the hospital with malignant hypertension and the balance studies varied from two days to two weeks. During this period on drug therapy and in association with the establishment of sodium balance on a 100 mEq diet, there was always a fall in PRA. Nevertheless, in all five patients in whom PRA levels were elevated prior to sodium balance, the values remained elevated above a normal range throughout the first study period when they were in balance on a 100 mEq sodium intake.
SERUM ELECTROLYTES AND UREA NITROGEN (SUN) ON THE INITIAL ADMISSION WITH MALIGNANT HYPERTENSION
Immediately upon admission in the malignant phase of hypertension and before balance was achieved on a 100 mEq sodium diet, serum sodium averaged 136.6 mEq/L (range 130 to 143) and serum potassium averaged 3.5 mEq/L (range 2.5 to 4.8) (Table 3) . SUN was elevated in 17 of 22 patients and correlated well with long-term prognosis in the series. To date, five of the six patients with SUN levels above 50 mg% have died (50% survival at the end of one year) in contrast to two deaths in 15 patients with initial SUN less than 50 mg% (93% one-year survival).
After sodium balance was achieved and potassium was repleted during the initial admission, serum sodium averaged 136.8 mEq/L (range 132 to 141), and potassium averaged 4.3 mEq/L (range 3.6 to 5.4).
Out of the eight patients who had increased PRA initially, seven remained well enough for the follow-up studies summarized in Figure 1 and detailed in Table 5 . In all seven, PRA fell Months after 1st adm ASR (100 mEq Na) Sup PRA (100 mEq Na) Amb PRA (100 mEq Na) E.S.
Months after 1st adm ASR (100 mEq Na) Sup PRA (100 mEq Na) Amb PRA (100 mEq Na) J.B.
Months after 1st adm ASR (100 mEq Na) Sup PRA (100 mEq Na) Amb PRA (100 mEq Na) Amb PRA (10 mEq Na) *Key: PRA = plasma renin activity (ng/100 ml/3 hr); ASR = aldosterone secretion rate (jig/24 hr); Sup = supine; Amb = ambulatory; adm = admission (see text for elaboration). A. ASR and PRA returned to normal during follow-up period Months after 1st adm ASR (100 mEq Na) Sup PRA (100 mEq Na) Amb PRA (100 mEq Na) Months after 1st adm ASR (100 mEq Na) Sup PRA (100 mEq Na) Amb PRA (100 mEq Na) Amb PRA (10 mEq Na) Months after 1st adm ASR (100 mEq Na) Sup PRA (100 mEq Na) Amb PRA (100 mEq Na) Amb PRA (10 mEq Na) Months after 1st adm ASR (100 mEq Na) Sup PRA (100 mEq Na) Amb PRA (100 mEq Na) Months after 1st adm ASR (100 mEq Na) Months after 1st adm ASR (100 mEq Na) Sup PRA (100 mEq Na) Amb PRA (100 mEq Na) B. ASR remained elevated; Months after 1st adm ASR (100 mEq Na) Sup PRA (100 mEq Na) Amb PRA (100 mEq Na) Months after 1st adm ASR (100 mEq Na) Sup PRA (100 mEq Na) Amb PRA (100 mEq Na) Amb PRA (10 mEq Na) to normal after 1 to 12 months of antihypertensive therapy.
These reductions in PRA with antihypertensive therapy cannot be attributed to sodium depletion at the time of the original study with subsequent repletion. PRA determinations were made only after sodium balance was achieved on a high mEq sodium diet, and the average serum sodium at the time of initial study in this subset of patients (135.8 mEq/L) was not significantly lower than during the final study (136.3 mEq/L).
In only one patient ( Months after 1st adm ASR (100 mEq Na) Sup PRA (100 mEq Na) Amb PRA (100 mEq Na) Amb PRA (10 mEq Na) Months after 1st adm ASR (100 mEq Na) Sup PRA (100 mEq Na) Amb PRA (100 mEq Na) Months after 1st adm ASR (100 mEq Na) Sup PRA (100 mEq Na) Amb PRA (100 mEq Na) Months after 1st adm ASR (100 mEq Na) Sup PRA (100 mEq Na) Amb PRA (100 mEq Na) Months after 1st adm ASR (100 mEq Na) Sup PRA (100 mEq Na) Amb PRA (100 mEq Na) Months after 1st adm ASR (100 mEq Na) Sup PRA (100 mEq Na) Amb PRA (100 mEq Na) Table 4 for key to abbreviations. fPostoperative studies. JASR after administration of desoxycorticosterone acetate (see text).
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PRA rose from normal to levels that were persistently elevated on seven follow-up studies during 46 months of antihypertensive therapy. Hyperaldosteronism and hypertension difficult to control persisted throughout, and he developed renal failure.
In some patients PRA fell rather promptly with effective therapy, as is illustrated by the course of J.W. in Figure 2 . After sodium repletion, PRA fell but not to normal levels. During this period the patient was also on methyldopa in a maintenance dose of 2 g daily which had little effect on blood pressure. Reduction of PRA to values that were frequently normal, however, occurred only after blood pressure was substantially reduced by adding guanethidine to the regimen. PRA was entirely normal ( Table 5 , patient 8) after three months of antihypertensive therapy.
MEAN
LONGITUDINAL EVALUATION OF THE HYPERALDOSTERONISM AND ITS DISSOCIATION FROM PLASMA RENIN ACTIVITY
Although only eight (36%) of the patients had elevated renin activity initially, increased aldosterone secretion was present at this time in 19 (86%). Of these 19 with initially elevated aldosterone secretion, 13 remained well enough for follow-up studies.
Of the 13 patients evaluated longitudinally, aldosterone secretion returned to normal with antihypertensive drug therapy in six (patients 4, 5, 6, 7, 8, and 12; detailed data in Tables 5  and 6 ). Figure 3 summarizes the reversal of the hyperaldosteronism in these six patients. In the initial study aldosterone was increased in all, and renin activity was increased in all but one, a patient who never had increased renin activity, even on the night of admission before sodium repletion was begun. At the time of the final study, aldosterone secretion had returned to normal in all of these patients, and PRA was at or near the normal range.
However, at some phase of the "recovery period," elevated aldosterone secretion was present without the expected increase in PRA.. This dissociation of aldosterone secretion from PRA persisted for up to 12 months in some of the patients. From a diagnostic point of view, an aldosterone-producing adenoma might be suspected if the evaluation were limited to this phase of dissociation of aldosterone from PRA. The data from two of these patients illustrate the potential for a misdiagnosis:
Patient C.F.W. (patient 5, Table 5 ) had typical "secondary aldosteronism" during the initial admission, with PRA of 2,600 ng/100 ml in the supine position. At 12 months ASR remained elevated even though renin was normal and increased only to 305 ng/100 ml with ambulation while on a 10 mEq sodium diet. These findings might be attributed to an aldosterone-producing adenoma, yet aldosterone secretion had fallen to normal at 18 months and renin responded normally to a low sodium stimulus at that time. Dissociation between aldosterone secretion and renin was present in CM. (patient 12) even at the time of admission with malignant hypertension. Increased ASR persisted through the study period at nine months when the failure of renin to rise with low sodium stimulus also could have been attributed to an aldosterone-producing adenoma. At 28 months, however, ASR had returned to normal, and the low sodium stimulus produced a normal increase in renin.
Clearly, in both of these patients the further follow-up studies were necessary to insure that the dissociation between ASR and PRA in the postmalignant hypertension period was not mistaken for an aldosteroneproducing adenoma.
That malignant hypertension does not preclude the diagnosis of an aldosteroneproducing adenoma is illustrated by one of the patients in this series. J.E. (patient 13, Table  6 ) is a 56-year-old Caucasian man, who was admitted with very recent onset of malignant hypertension following a 23-year history of benign hypertension. He was known to have had hypokalemia in the absence of diuretic therapy for at least 18 months prior to developing malignant hypertension. On admission to the hospital during the acute phase of malignant hypertension, he had very low renin activity that was unresponsive to low sodium stimulus, together with elevated ASR. Serum potassium was 2.8 mEq/L. Treatment with the adrenocortical inhibitor, aminoglutethimide, produced control of the blood pressure, reversal of potassium wasting, and a rise in PRA to over 700 ng/100 ml. After it was discontinued, PRA fell again to undetectable levels, and the ASR was 416 fig/M hr. Removal of the left adrenal gland which contained a 0.5-cm cortical adenoma restored aldosterone secretion to normal. Vigorous antihypertensive therapy was required postoperatively for several months, after which all antihypertensive drugs were gradually withdrawn. He is now normotensive.
Plasma renin activity in this patient was suppressed preoperatively; no PRA could be detected by this method of assay even after ambulation on a 10 mEq sodium diet.
MARKED, PROLONGED ELEVATION OF PRA IN THE POSTMALIGNANT PERIOD FOLLOWED BY HIGH ASR, LOW PRA, AND DISCOVERY OF AN ADRENAL ADENOMA AT AUTOPSY
A.W. was a 50-year-old black female with at least seven years of hypertension (patient 10, Table 5 ). On admission with malignant hypertension and hypertensive encephalopathy, she had a PRA of 24,000 ng/100 ml when in balance on a 100 mEq sodium diet, 
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the second highest seen in the series. Even at the end of four months of antihypertensive therapy, PRA remained quite elevated at 10,000 ng/100 ml. After 20 months of therapy, ASR remained elevated, but PRA had returned to normal. This dissociation between aldosterone and renin persisted at 24 and 26 months after the initial episode, and at this time PRA rose only slightly (370 ng/100 ml) with ambulation on a 10 mEq sodium diet. While waiting for the results of the last study, she had a fatal cerebral hemorrhage and at autopsy was found to have a yellow 0.6 X 0.8 cm adrenal cortical adenoma (Fig. 4) . Histologically, the adenoma was not sharply demarcated from surrounding tissue, and there also was evidence of diffuse cortical hyperplasia in both glands which included focal areas of vacuolated cells. The biochemical findings strongly suggest that this was an aldosterone-producing adenoma, but the definitive proof, cure of the hyperaldosteronism after removing the tumor, unfortunately is lacking.
In addition to the cases already discussed, there were ten patients with hyperaldosteronism which has been less well defined.
In four of these ten cases of undefined aldosteronism, follow-up studies were conducted. All had elevated aldosterone secretion together with normal or suppressed PRA during some phase of the study.
One patient had typical secondary aldosteronism initially with a PRA of 24,779 ng/100 ml, the highest in the series (patient 9, Table 5 ). After 16 months of therapy, PRA fell to normal. The autonomous hyperaldosteronism persisted at the eighteenth month of follow-up, but subsequently, the patient's renal function deteriorated to the point that no exploratory surgery was feasible, and he died because of renal failure.
Two patients had high ASR with normal PRA initially (patients 14 and 15, Table 6 ). This aldosteronism without increased PRA persists at 38 and 35 months, respectively, but surgery has not been undertaken yet because
H
Right adrenal gland with adrenal cortical adenoma removed at necropsy from A.W. (patient 10).
of normal ASR on two occasions during the eighteen-month follow-up study in patient A.M.W. and because ASR was suppressed to normal by desoxycorticosterone acetate in S.C. Follow-up studies on these two patients are continuing.
M.S. (patient 16, Table 6 ) is a 25-year-old black female who at the time of admission with malignant hypertension and during six subsequent studies over a 34-month period has had high ASR with suppressed PRA. The ASR was not reduced by desoxycortiocosterone acetate. On abdominal exploration she was found to have bilateral adrenal enlargement, and the extirpated left adrenal showed diffuse hyperplasia of the cortex with disruption of the normal cortical architecture (Fig. 5) . Postoperatively, she continues to have hypertension with hyperaldosteronism and low renin. In any other context she would be considered to have "pseudoprimary aldosteronism" due to bilateral adrenal hyperplasia 21 or "idiopathic aldosteronism." 22 In six of these ten patients, no follow-up studies were possible because of progressive deterioration of renal function. Five of these six had high aldosterone secretion with normal PRA when in the malignant phase, and only one had high renin activity with the hyperaldosteronism.
Discussion EFFECT OF ANTIHYPERTENSIVE THERAPY ON ELEVATED PLASMA RENIN ACTIVITY IN MALIGNANT HYPERTENSION
Thirty-six per cent of the patients in this series had elevated PRA during the initial admission with acute malignant hypertension. One additional patient developed increased PRA during the follow-up period, making a total of 41% of malignant hypertensives with high PRA at some time (patients with renal artery stenosis were excluded from the study). Clearly, malignant hypertension can occur without elevated PRA, and in fact, three patients had neither increased PRA nor high ASR.
After reduction of arterial pressure, PRA fell to normal in 87% of those in whom it was elevated. This reduction cannot be attributed simply to correction of an initial sodium deprivation, as suggested by Brown, 7 because the initial studies were conducted with the patients in balance on a 100 mEq sodium diet and with a serum sodium that was not . 
Photomicrograph of adrenal cortex from M.S. (patient 16
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significantly different from that when the renin became normal. Nor can the reduction be attributed to a specific pharmacological effect of methyldopa on renin release; some of the patients were on guanethidine which does not lower renin in essential hypertension. 23 Also, in the study by Mohammed et al., 24 the effect of methyldopa was seen in five days, whereas longer periods were usually required in these patients. Rather, the reduction of renin correlates best with the known healing of renal arterioles that follows treatment of the malignant hypertension.
1 '
2
The reduction of renin by lowering pressure and the absence of elevated renin in many cases are consistent with the idea that high arterial pressure (rather than elevated renin) is the primary event in malignant hypertension 25 producing arteriolar damage which mediates the clinical syndrome. Those cases in which the hypertensive arteriolopathy exists without increased PRA or ASR perhaps represent an early stage of the disease. In others the progressive arteriolopathy leads to a cascade of events with the development of increased PRA and a resultant elevation of ASR that further augments the hypertension. By removing the primary stimulus to this vicious cycle with antihypertensive therapy, the hormonal changes often revert to normal, and control of the hypertension becomes easier. The improved response to antihypertensive therapy seen after acute 26 and longterm 27 reduction of markedly elevated arterial pressure could be mediated in part by these hormonal changes.
HYPERALDOSTERONISM WITHOUT INCREASED PRA IN THE POSTMALIGNANT PHASE OF HYPERTENSION
Following treatment for malignant hypertension, six patients had a period of transient hyperaldosteronism during which PRA was not increased and was occasionally suppressed. The potential for an incorrect diagnosis of primary aldosteronism during this period is obvious. This reversible dissociation of hyperaldosteronism from renin suggests either that the feedback regulation of aldosterone by angiotensin is quantitatively deranged during this period or that an unidentified nonangiotensin hormone capable of stimulating aldosterone secretion is elevated during malignant hypertension and in the recovery phase. Certainly, there is evidence that factors other than angiotensin can influence aldosterone secretion, 28 and such an explanation cannot be excluded. Present knowledge, however, permits the following hypothesis based on the assumption that angiotensin is a major regulator of aldosterone secretion in man (Fig. 6) .
Chronic stimulation of aldosterone-secreting cells by high levels of angiotensin would be expected to lead to hyperplasia and hyperfunction of these cells. 2 * When renin levels are lowered with antihypertensive therapy, persistent hyperplasia with a delay in resetting the feedback control mechanism to normal would allow these cells to respond excessively to normal amounts of angiotensin. In the six patients depicted in Figure 2 , such a derangement in the control of aldosterone secretion would have been a transient phenomenon. In one patient in this group, the suppression of ASR by DOCA indicates that aldosterone secretion is not completely autonomous during this phase; rather, the angiotensin feedback control mechanism is quantitatively disordered. This resembles the transient hyperparathyroid state that may follow correction of renal failure. 30 ' 31 The excessive and chronic stimulation of the parathyroid glands by the hypocalcemia of renal failure apparently causes them to develop a hyperplasia and hyperfunction that are slow to return to normal after removal of the stimulus. In some patients in the post-renal failure state, autonomously functioning parathyroid adenomas develop and require resection for cure 30 -31 ("tertiary hyperparathyroidism" 32 ). The fact that the period of transient dissociation of hyperaldosteronism from renin persists for up to ten months raises the possibility that a more permanent and autonomous state of disordered aldosterone secretion might develop in some patients, analogous to "tertiary hyperparathyroidism." Certainly, aldosterone secretion has not returned to normal in several patients in this series at the present point of follow-up, and Laragh has previously reported a patient with persistent hyperaldosteronism following a period of high PRA. 21 Conceivably, in the setting of hyperplasia with a deranged control mechanism, cell lines totally lacking feedback control could evolve. These might be expressed anatomically either as bilateral hyperplasia or as adenomas developing within hyperplastic glands. It is conceivable that such a sequence could have accounted for the development of an adrenal adenoma in the presence of adrenal hyperplasia in patient A.W., who had very high levels of PRA for at least a year followed by a period of high ASR and suppressed PRA prior to her fatal cerebral hemorrhage. With present information a distinction in this patient from a primary adenoma antedating and causing the malignant hypertension is impossible, a dilemma illustrated also by previously reported patients who had aldosteronism with single 3334 or multiple 35 adenomas detected at some time after malignant hypertension or renal disease which could have produced excessive renin secretion as a primary hormonal event. M.S. (patient 16), with known bilateral hyperplasia and autonomous aldosterone secretion, must be considered in the same context. The Suppleme present evidence only raises to the level of an attractive speculation the possibility that a tertiary type of autonomous aldosteronism could result from chronic stimulation of the adrenals by angiotensin.
DEVELOPMENT OF MALIGNANT HYPERTENSION WITH PRIMARY ALDOSTERONISM
One patient in this series (J-E.) with an aldosterone-producing adenoma developed malignant hypertension following a period in which evidence for aldosteronism was associated with benign hypertension, and his hypertension was cured by extirpation of the adenoma. The primary role of the aldosteroneproducing adenoma seems apparent in this case, which illustrates, together with the similar case reported by Kaplan, 12 that aldosterone-producing adenomas do not confer a special protection from malignant hypertension.
